Developing new therapeutic options for the treatment of liver cirrhosis through the epigenomic and transcriptome signature

通过表观基因组和转录组特征开发治疗肝硬化的新治疗方案

• 批准号: 20K17006
• 负责人: Vilaseca Marina
• 金额: $ 2.66万
• 依托单位: Institute of Physical and Chemical Research
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Early-Career Scientists
• 财政年份: 2020
• 资助国家: 日本
• 起止时间: 2020-04-01 至 2023-03-31
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-20K17006/
• 关键词: single cell; cirrhosis regression; liver cirrhosis; single-cell; epigenome

We were analyzing how the different cell pathways are changing during both processes. On single nuclei-ATAC-seq, we are confirming some results that I already obtainedwith bulk ATAC. We are observing how regressed Hepatic stellate cells (HSC) have more accessible chromatin than healthy HSC, although they havesimilar gene expression profiles, which was one of the initial hypothesis of this project. However, we are not seeing this only in HSC but alsoin Liver Sinusoidal Endothelial Cells, which are in close contact with HSC and hepatocytes.

我们分析了在这两个过程中不同的细胞通路是如何变化的。 在单核-ATAC-seq上，我们证实了我已经用批量ATAC获得的一些结果。我们正在观察退化的肝星状细胞（HSC）如何比健康的HSC具有更易接近的染色质，尽管它们具有相似的基因表达谱，这是本项目的最初假设之一。然而，我们不仅在HSC中看到这一点，而且在与HSC和肝细胞密切接触的肝窦内皮细胞中也看到这一点。